Thrombotic occlusion of the coronary artery, which triggers acute myocardial infarction, is
one of the major causes of death in the USA. Currently, arterial occlusions are treated with …

Fibrinolytic drugs have been successfully used to manage acute thrombotic and
thromboembolic conditions. However, their narrow administration time window, rapid …

Recombinant DNA technology has allowed large-scale production of the physiological, fibrin-
specific, plasminogen activators tissue-type plasminogen activator (t-PA) and single-chain …

Cardiovascular diseases that result from thrombosis of critically situated blood vessels
remain the leading cause of death in industrialized countries. One primary clinical treatment …

Various plasminogen activators have been routinely used for the treatment of thrombotic
diseases. However, these agents possess various problems eg short half life and other …

Rapid restoration of patency of the infarct-related artery is the key to preserving myocardium
and improving survival. This understanding has led to the application of genetic engineering …

Background Thrombolytic therapy reduces mortality in patients with acute myocardial
infarction, but significant limitations exist with the use of currently available agents. In the …

Thrombolytic therapy by infusion of analogs of tissue plasminogen activator (tPA), other
recombinant-based plasminogen activators (eg, alteplase, reteplase, and tenecteplase) …

Thrombus formed in blood vessel is a progressive process, which would lead to life-
threatening thrombotic diseases such as ischemic stroke. Unlike other diseases, the …

Plasminogen activator therapy for acute myocardial infarction has become standard medical
practice. Bleeding complications, however, limit the utility of the currently available agents …